Dr. Gottlieb is a Professor of Pediatrics and Medicine at the Barbara Davis Center at the University of Colorado School of Medicine. He is the holder of the Orr Family Endowed Chair in Adult Diabetes at the BDC. His areas of research have included the immune mechanisms underlying type 1 diabetes and other autoimmune diseases focusing on the role of antigen-specific T cells and B cells, which drive the immune process. Dr. Gottlieb has published more than 190 papers in the field. He has been a member of NIDDK-sponsored Type 1 Diabetes TrialNet from its onset and the chair of the Collaborative Mechanistic Studies Panel. He has been a clinical investigator on many of the intervention trials performed through TrialNet, Immune Tolerance Network (ITN) or industry, in both prediabetes (Stage 1 and 2) and clinical diabetes (Stage 3) over the last 20 years.
Dr. Gottlieb has been involved in translational research at the BDC and along with Dr. Aaron Michels spun out IM Therapeutics, Inc. from the BDC and the University of Colorado to develop small molecules to prevent the presentation of self-peptides in type 1 diabetes and other autoimmune diseases. Dr. Gottlieb received his M.D. from Rutgers Medical School and completed his residency in Internal Medicine and fellowship in Endocrinology at the University of Massachusetts Medical School. He did his post-doctoral work in Immunology at the Weizmann Institute in Rehovot, Israel.